pembrolizumabNivolumabcetuximabPD-1imethotrexatedocetaxelSMNPhead and neck squamous cell carcinoma
…, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectabl…
1articles mentioning drugs
8drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: PD-1i ×
PD-1i
This drug is selected. Its supporting articles are shown below.